Therapy by Design: How Genetics Shape Treatment Decisions (2025)

Keri Miller will provide an in-depth exploration of genetic cancer genes, focusing on their role in cancer diagnosis and management. A detailed analysis of the Oncotype DX test will be presented, including an explanation of how it works, what it measures, and its significance in guiding treatment decisions for breast cancer patients.

Learning Objectives:

Review the significance of understanding genetic cancer genes for targeted therapy.
Outline how Oncotype DX influences treatment decisions, particularly in hormone receptor-positive, HER2-negative breast cancer, and how it can reduce overtreatment and personalize therapy.
Discuss the determinants of clinical decision making based on inherited genetic variations.

Credit Information

Activity Number	Credit Amount	Accreditation Period
2025-095	1 CE	June 24, 2025 - June 18, 2027

Instructor

Keri Miller, MHA, ODS-C Instructor

Keri Miller, MHA, ODS-C, is the current SEER Manager for the Alaska Native Tumor Registry, where she has played a crucial role in managing and analyzing cancer data to support the unique healthcare needs of the Alaska Native population. In addition to her ODS credential, Keri holds a master’s in health administration. She has a strong commitment to precision and quality in cancer registry operations, and she is dedicated to advancing cancer research and improving patient outcomes.

Learning Module

Member

Non-Member

Instructor

Keri Miller, MHA, ODS-C

Credit Information

Error